Loading…
Zenith Drugs (ZENITHDRUG)₹39.60+2.33%Pharmaceuticals
In the Mar 2026 quarter (standalone), Zenith Drugs reported sales of ₹92.65 Cr, up 40.8% from Mar 2025, and net profit of ₹2.01 Cr, up 99.0% year on year. For the year to Mar 2026, sales were ₹170 Cr and net profit ₹4.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 68.81 | 61.80 | 67.74 | 65.82 | 77.75 | 92.65 |
| Expenses | 57.88 | 55.94 | 60.91 | 58.91 | 71.93 | 86.81 |
| Operating Profit | 11.04 | 6.02 | 7.02 | 7.03 | 6.02 | 6.02 |
| OPM % | 16.0% | 9.0% | 10.0% | 10.0% | 8.0% | 6.0% |
| Other Income | −0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 2.99 |
| Interest | 0.99 | 1.99 | 1.01 | 1.99 | 2.99 | 2.99 |
| Depreciation | 0.99 | 0.99 | 0.99 | 1.99 | 2.99 | 2.99 |
| Profit before tax | 7.99 | 5.99 | 6.01 | 3.99 | 2.01 | 2.99 |
| Tax % | 25.1% | 32.1% | 0.0% | 59.1% | 0.0% | 48.0% |
| Exceptional items | −1.08 | −0.02 | 0.00 | −0.26 | −0.23 | 0.00 |
| Net Profit | 6.01 | 4.01 | 6.01 | 1.01 | 2.01 | 2.01 |
| EPS (Rs) | 4.77 | 2.25 | 3.35 | 0.85 | 1.37 | 0.95 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 77.69 | 71.75 | 91.64 | 115 | 131 | 132 | 170 |
| Expenses | 70.92 | 63.87 | 84.81 | 105 | 114 | 119 | 159 |
| Operating Profit | 7.02 | 7.03 | 7.02 | 9.03 | 17.06 | 14.05 | 12.04 |
| OPM % | 9.0% | 10.0% | 8.0% | 8.0% | 13.0% | 10.0% | 7.0% |
| Other Income | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 4.99 |
| Interest | 1.01 | 0.99 | 1.99 | 1.99 | 2.99 | 3.99 | 5.99 |
| Depreciation | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 | 5.99 |
| Profit before tax | 4.99 | 5.01 | 3.99 | 7.01 | 12.99 | 8.99 | 4.99 |
| Tax % | 30.1% | 33.1% | 27.1% | 27.0% | 28.1% | 23.1% | 27.0% |
| Exceptional items | 0.02 | 0.00 | 0.00 | 0.00 | −1.12 | −0.16 | −0.23 |
| Net Profit | 3.01 | 3.01 | 3.01 | 5.01 | 10.02 | 7.01 | 4.01 |
| EPS (Rs) | — | — | — | — | 5.58 | 4.19 | 2.31 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 0.0% | 0.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.39 | 0.39 | 0.39 | 0.39 | 16.94 | 16.93 | 16.94 |
| Reserves | 5.99 | 8.99 | 11.99 | 16.99 | 44.93 | 51.96 | 57.94 |
| Borrowings | 12.01 | 15.02 | 17.02 | 25.03 | 24.04 | 49.01 | 55.05 |
| Other Liabilities | 24.98 | 20.97 | 36.90 | 53.92 | 47.84 | 44.00 | 56.86 |
| Total Liabilities | 43.97 | 46.97 | 65.90 | 96.93 | 134 | 161 | 188 |
| Fixed Assets | 6.02 | 9.03 | 10.04 | 11.04 | 11.04 | 40.15 | 41.13 |
| CWIP | 3.01 | 0.00 | 0.00 | 0.00 | 4.01 | 3.01 | 10.01 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 34.94 | 36.94 | 55.86 | 85.89 | 119 | 118 | 136 |
| Inventories | 4.01 | 7.01 | 12.03 | 24.06 | 26.05 | 40.10 | 42.08 |
| Trade receivables | 25.03 | 23.04 | 32.05 | 49.02 | 67.07 | 61.03 | 73.08 |
| Cash & equivalents | 0.00 | 2.01 | 3.01 | 0.00 | 9.01 | 0.00 | 0.00 |
| Total Assets | 43.97 | 46.97 | 65.90 | 96.93 | 134 | 161 | 188 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2.99 | −0.99 | 4.99 | −3.99 | −15.97 | −4.99 | 8.99 |
| Cash from investing activity | −4.98 | −1.99 | −2.99 | −1.99 | −4.98 | −30.90 | −13.96 |
| Cash from financing activity | 1.01 | 3.01 | −1.01 | 6.01 | 30.02 | 28.01 | 5.01 |
| Net cash flow | 0.00 | 0.00 | 1.01 | 0.00 | 9.01 | −8.01 | 0.00 |
| Capex | 4.92 | 1.42 | 2.56 | 1.67 | 1.41 | 32.22 | 3.03 |
| Free cash flow | −1.01 | −2.01 | 2.01 | −6.01 | −21.01 | −37.05 | −4.99 |
| CFO / OP % | 71.0% | 7.0% | 88.0% | −27.0% | −70.0% | −25.0% | 86.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 118 | 118 | 127 | 156 | 187 | 166 | 155 |
| Inventory days | 29 | 52 | 61 | — | 249 | 277 | 126 |
| Days payable | 156 | 156 | 174 | — | 413 | 282 | 167 |
| Cash conversion cycle | −7 | 17 | 16 | 157 | 25 | 163 | 117 |
| Working capital days | 13 | 23 | 20 | 38 | 110 | 97 | 76 |
| ROCE % | — | 28.1% | 24.1% | 25.0% | 28.1% | 13.0% | 9.1% |
For the Mar 2026 quarter, Zenith Drugs reported sales of ₹92.65 Cr, up 40.8% year on year and net profit of ₹2.01 Cr, up 99.0% year on year. The operating margin was 6.0%.
Zenith Drugs' sales for the year to Mar 2026 were ₹170 Cr.
Net profit for the year to Mar 2026 was ₹4.01 Cr. Earnings per share over the same trailing period were ₹2.31.
Zenith Drugs reported borrowings of ₹55.05 Cr at Mar 2026, against cash and equivalents of ₹0 Cr.
Cash from operations was ₹8.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹4.99 Cr.